2seventy bio accepts Bristol Myers’ takeover bid

11 March 2025

Shares of US biotech 2seventy Bio (Nasdaq: TSVT) skyrocketed almost 76% to $4.92 today, as it agreed to a takeover bid from US pharma major Bristol Myers Squibb (NYSE: BMY), which is looking to enhance its CAR T-cell therapy business.

BMS is offering to acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of about $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025.

The deal value is well below Leerink Partners’ $487 million valuation for 2seventy based on the biotech’s expected future cash flows, as well as $9 a share from Citi in February.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology